Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma

31 Oct 2016

Abstract excerpt

Janus kinases (JAKs) classically signal by activating STAT transcription factors but can also regulate gene expression by epigenetically phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large B-cell lymphomas (DLBCLs), JAK signaling is a feature of the activated B-cell (ABC) subtype and is triggered by autocrine production of IL-6 and IL-10. Whether this signaling involves STAT activation,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous lymphoproliferative disorders research
Share to Cytokine Signaling Pathways and Interactions
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27799566
DOI: 10.1073/pnas.1610970113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphomaPMID 27799566Read ↗

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.Semantic proximity Read ↗

Janus kinase deregulation in leukemia and lymphoma.Semantic proximity Read ↗

STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

STAT3 Inhibitors: Finding a Home in Lymphoma and LeukemiaSemantic proximity Read ↗

Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic ImplicationsSemantic proximity Read ↗

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomasSemantic proximity Read ↗

Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).Semantic proximity Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B‐cell lymphomaSemantic proximity Read ↗

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphomaSemantic proximity Read ↗

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.